Investors will be keeping a close eye on Pfizer's earnings when they report first quarter results on May 5th. Pfizer has been heavily focused on the M&A business with its bid to buy British drug maker AstraZeneca. On Friday, Pfizer increased its bid for the company from $10 billion to $14 billion. Analysts expect the pharmaceutical company to earn $0.55 a share on $12.07 billion in revenue. If Pfizer meets Wall Street forecasts, it would represent a decline in sales growth of 10.6 percent from a year ago.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.